BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 26577047)

  • 21. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary biliary cirrhosis in adults.
    Momah N; Lindor KD
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):427-33. PubMed ID: 24580040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode.
    Kotb MA
    Int J Mol Sci; 2012; 13(7):8882-8914. PubMed ID: 22942741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Old and novel therapies for primary biliary cirrhosis.
    Parés A
    Semin Liver Dis; 2014 Aug; 34(3):341-51. PubMed ID: 25057957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic advances for primary biliary cholangitis: the old and the new.
    Wang L; Zhang FC; Zhang X
    Eur J Gastroenterol Hepatol; 2016 Jun; 28(6):615-21. PubMed ID: 26862931
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
    Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
    Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Therapies on Primary Biliary Cirrhosis.
    Czul F; Levy C
    Clin Liver Dis; 2016 Feb; 20(1):113-30. PubMed ID: 26593294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary biliary cirrhosis: overlaps with other autoimmune disorders.
    Floreani A; Franceschet I; Cazzagon N
    Semin Liver Dis; 2014 Aug; 34(3):352-60. PubMed ID: 25057958
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in pharmacotherapy for primary biliary cirrhosis.
    Mousa HS; Lleo A; Invernizzi P; Bowlus CL; Gershwin ME
    Expert Opin Pharmacother; 2015 Apr; 16(5):633-43. PubMed ID: 25543678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Primary biliary cirrhosis].
    Chon CY; Park JY
    Korean J Hepatol; 2006 Sep; 12(3):364-72. PubMed ID: 16998288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis.
    Combes B; Emerson SS; Flye NL; Munoz SJ; Luketic VA; Mayo MJ; McCashland TM; Zetterman RK; Peters MG; Di Bisceglie AM; Benner KG; Kowdley KV; Carithers RL; Rosoff L; Garcia-Tsao G; Boyer JL; Boyer TD; Martinez EJ; Bass NM; Lake JR; Barnes DS; Bonacini M; Lindsay KL; Mills AS; Markin RS; Rubin R; West AB; Wheeler DE; Contos MJ; Hofmann AF
    Hepatology; 2005 Nov; 42(5):1184-93. PubMed ID: 16250039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
    Hay JE
    Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guidelines for therapy of autoimmune liver disease.
    Ishibashi H; Komori A; Shimoda S; Gershwin ME
    Semin Liver Dis; 2007 May; 27(2):214-26. PubMed ID: 17520519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of primary biliary cirrhosis.
    Poupon R; Poupon RE
    Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):615-28. PubMed ID: 10976018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis and management of primary biliary cirrhosis.
    Ali AH; Carey EJ; Lindor KD
    Expert Rev Clin Immunol; 2014 Dec; 10(12):1667-78. PubMed ID: 25382237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Rust C; Beuers U
    Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.
    Corpechot C; Poujol-Robert A; Wendum D; Galotte M; Chrétien Y; Poupon RE; Poupon R
    Liver Int; 2004 Jun; 24(3):187-93. PubMed ID: 15189267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
    Linares Rodríguez A
    Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
    [No Abstract]   [Full Text] [Related]  

  • 39. New Therapeutic Strategies for Primary Sclerosing Cholangitis.
    Williamson KD; Chapman RW
    Semin Liver Dis; 2016 Feb; 36(1):5-14. PubMed ID: 26870928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Toward precision medicine in primary biliary cholangitis.
    Carbone M; Ronca V; Bruno S; Invernizzi P; Mells GF
    Dig Liver Dis; 2016 Aug; 48(8):843-50. PubMed ID: 27324985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.